Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 30/100

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Key Takeaway: Corcept Therapeutics is facing a securities fraud class action lawsuit as they are accused of failing to disclose crucial information regarding their lead product candidate, relacorilant. The lawsuit stems from the company's representation of high FDA approval likelihood, which contradicted the recent FDA Complete Response Letter that requested further evidence of effectiveness. Following this disclosure, Corcept's shares plummeted by over 50%, prompting investor action. The deadline for investors to join the class action is April 21, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics is facing a securities fraud class action lawsuit due to undisclosed material information.
  • The FDA issued a Complete Response Letter for relacorilant, requiring additional evidence of effectiveness.
  • The company's stock price dropped by 50.4% following the negative FDA news.

Full Press Release Details

NEW YORK and NEW ORLEANS, March 17, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
If you purchased shares of Corcept and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-cort/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 21, 2026.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file for lead plaintiff in the Corcept case?

The deadline to file for lead plaintiff is April 21, 2026.

What was the reason for the lawsuit against Corcept Therapeutics?

Corcept is charged with not disclosing crucial information during the Class Period.

What caused the drop in Corcept's share price?

The share price dropped after the FDA issued a Complete Response Letter for relacorilant.

How much did Corcept's shares decline on December 31, 2025?

Corcept's shares fell by $35.40 or 50.4% on December 31, 2025.

Who can I contact for more information about the lawsuit?

You can contact Lewis Kahn at KSF toll-free at 1-877-515-1850 or via email.

Last updated: Mar 18, 2026